Comparative Immune Response after Vaccination with SOBERANA® 02 and SOBERANA® plus Heterologous Scheme and Natural Infection in Young Children

Heterologous Memory T cell
DOI: 10.20944/preprints202309.0564.v1 Publication Date: 2023-09-12T02:52:11Z
ABSTRACT
(1) Background: SARS-CoV-2 infection is mostly accompanied by mild COVID-19 symptoms in children. However, the multisystem inflammatory syndrome (MIS-C) and long-term sequelae are often severe complications. Therefore, protection of pediatric population against with effective vaccines particularly important. Here we compare humoral cellular immune responses elicited children (n=15) aged 5-11 years vaccinated RBD-based combined a heterologous scheme SOBERANA® 02 Plus those from (n=10) 4-11 who recovered symptomatic COVID-19. (2) Methods: Blood samples were taken 14 days after last dose for 45-60 diagnosis Anti-RBD IgG ACE2-RBD inhibition assessed ELISA; IgA, cytokine cytotoxic related proteins profile determined multiplex assays. Total B T cell subpopulations IFN-γ release measured multiparametric flow cytometry using large panel antibodies vitro stimulation S1 peptides. (3) Results: Significant higher levels specific anti-RBD IgA capacity found comparison to Th1-like Th2-like CD4+ cells also significantly subjects. secretion central memory children, but no differences between both groups CD8+ effector, terminal naïve subpopulations. High IL-2, IL-6, IL-10 contrast low IL-4 suggesting predominant Th1 polarization. Cytotoxic-related granzyme A B, perforin granulin supernatant (4) Conclusions: Vaccination 02/ induces strong antibody response compared natural infections young
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)